176 related articles for article (PubMed ID: 25033777)
1. Analysis of risk-structured vaccination model for the dynamics of oncogenic and warts-causing HPV types.
Alsaleh AA; Gumel AB
Bull Math Biol; 2014 Jul; 76(7):1670-726. PubMed ID: 25033777
[TBL] [Abstract][Full Text] [Related]
2. Global stability of equilibria in a two-sex HPV vaccination model.
Elbasha EH
Bull Math Biol; 2008 Apr; 70(3):894-909. PubMed ID: 17999117
[TBL] [Abstract][Full Text] [Related]
3. The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer.
Malik T; Reimer J; Gumel A; Elbasha EH; Mahmud S
Math Biosci Eng; 2013 Aug; 10(4):1173-205. PubMed ID: 23906207
[TBL] [Abstract][Full Text] [Related]
4. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
Lehtinen M; Apter D
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM; Bazaldua OV; Vargas L; Reile E
Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
[TBL] [Abstract][Full Text] [Related]
6. Vaccination against multiple HPV types.
Elbasha EH; Galvani AP
Math Biosci; 2005 Sep; 197(1):88-117. PubMed ID: 16095627
[TBL] [Abstract][Full Text] [Related]
7. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus: current status and issues of vaccination.
Malik H; Khan FH; Ahsan H
Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
[TBL] [Abstract][Full Text] [Related]
9. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
11. Decreasing risk: impact of HPV vaccination on outcomes.
Hymel PA
Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
[TBL] [Abstract][Full Text] [Related]
12. The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study.
Brown VL; Jane White KA
Math Biosci; 2011 Jun; 231(2):126-34. PubMed ID: 21377481
[TBL] [Abstract][Full Text] [Related]
13. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
14. The HPV vaccination strategy: could male vaccination have a significant impact?
Brown V; White KA
Comput Math Methods Med; 2010 Sep; 11(3):223-37. PubMed ID: 20582762
[TBL] [Abstract][Full Text] [Related]
15. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.
Korostil IA; Peters GW; Law MG; Regan DG
Vaccine; 2013 Apr; 31(15):1931-6. PubMed ID: 23434388
[TBL] [Abstract][Full Text] [Related]
16. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
17. Getting to know human papillomavirus (HPV) and the HPV vaccines.
Smith GD; Travis L
J Am Osteopath Assoc; 2011 Mar; 111(3 Suppl 2):S29-34. PubMed ID: 21415377
[TBL] [Abstract][Full Text] [Related]
18. [Vaccination against human papillomavirus for the prevention of cervical cancer].
Quint WG; ter Harmsel WA; van Doorn LJ
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
[TBL] [Abstract][Full Text] [Related]
19. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
